Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors

Open access
Yap, Timothy A., O’Carrigan, Brent, Penney, Marina S., Lim, Joline S., Brown, Jessica S., de Miguel Luken, Maria J., Tunariu, Nina, Perez-Lopez, Raquel, Rodrigues, Daniel Nava, Riisnaes, Ruth, Figueiredo, Ines, Carreira, Suzanne, Hare, Brian, McDermott, Katherine, Khalique, Saira, Williamson, Chris T., Natrajan, Rachael, Pettitt, Stephen J., Lord, Christopher J., Banerji, Udai, Pollard, John, Lopez, Juanita, de Bono, Johann S. · 2020 · Journal of Clinical Oncology

Abstract

PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin. PATIENTS AND METHODS: This phase I trial assessed the ATR inhibitor M6620 (VX-970) as monotherapy (once or twice weekly) and combined with carboplatin (carboplatin on day 1 and M6620 on days 2 and 9 in 21-day cycles). Primary objectives were safety, tolerability, and maximum tolerated dose; secondary objectives included pharmacokinetics and antitumor activity; exploratory objectives included pharmacodynamics in timed paired tumor biopsies. RESULTS: Forty patients were enrolled; 17 received M6620 monotherapy, which was safe and well tolerated. The recommended phase II dose (RP2D) for once- or twice-weekly administration was 240 mg/m 2. A patient with metastatic colorectal cancer harboring molecular aberrations, including ATM loss and an ARID1A mutation, achieved RECISTv1.1 complete response and maintained this response, with a progression-free survival of 29 months at last assessment. Twenty-three patients received M6620 with carboplatin, with mechanism-based hematologic toxicities at higher doses, requiring dose delays and reductions. The RP2D for combination therapy was M6620 90 mg/m 2 with carboplatin AUC5. A patient with advanced germline BRCA1 ovarian cancer achieved RECISTv1.1 partial response and Gynecologic Cancer Intergroup CA125 response despite being platinum refractory and PARP inhibitor resistant. An additional 15 patients had RECISTv1.1 stable disease as best response. Pharmacokinetics were dose proportional and exceeded preclinical efficacious levels. Pharmacodynamic studies demonstrated substantial inhibition of phosphorylation of CHK1, the downstream ATR substrate. CONCLUSION: To our knowledge, this report is the first of an ATR inhibitor as monotherapy and combined with carboplatin. M6620 was well tolerated, with target engagement and preliminary antitumor responses observed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.19.02404

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 251

Metadata

Authors
Yap, T. A., O’Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J., Tunariu, N., Perez-Lopez, R., Rodrigues, D. N., Riisnaes, R., Figueiredo, I., Carreira, S., Hare, B., McDermott, K., Khalique, S., Williamson, C. T., Natrajan, R., Pettitt, S. J., Lord, C. J., Banerji, U., Pollard, J., Lopez, J., & de Bono, J. S.
Venue
Journal of Clinical Oncology
Published
2020-09-20
Volume
38
Issue
27
Pages
3195-3204
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3036123907
Cited by
251
References
4
FWCI
11.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.19.02404
The paper
Yap, T. A., O’Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J., Tunariu, N., Perez-Lopez, R., Rodrigues, D. N., Riisnaes, R., Figueiredo, I., Carreira, S., Hare, B., McDermott, K., Khalique, S., Williamson, C. T., Natrajan, R., Pettitt, S. J., Lord, C. J., . . . de Bono, J. S. (2020). Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.19.02404

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.